预约演示
更新于：2026-05-06
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2026-05-06
概要
基本信息
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
39
项与 氨酚羟考酮 相关的临床试验NCT07017452
Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
64
项与 氨酚羟考酮 相关的文献（医药）2025-09-01AMERICAN SURGEON
Outcomes After Implementation of an Enhanced Recovery Protocol for Minimally Invasive Repair of Pectus Excavatum
Article
作者: Spector, Chelsea ; Ngo, Lisa ; Laituri, Carrie ; Levene, Tamar ; Katz, Danielle ; Samuels, Shenae ; Motta, Monique
Background:
Surgical repair of pectus excavatum is commonly associated with significant post-operative pain requiring prolonged hospital stays and critical care admission for sedative and analgesic infusions. By implementing an enhanced recovery after surgery (ERAS) protocol for patients undergoing minimally invasive pectus repair, we aimed to reduce length of hospital stay, need for higher level monitored care, and opioid utilization.
Methods:
A retrospective chart review was performed for all patients under the age of 25 years who underwent Nuss bar insertion at our institution between January 2011 and May 2021. The primary outcomes were hospital length of stay, intensive care unit (ICU) utilization, and opioid consumption before and after the implementation of the ERAS protocol in December 2017.
Results:
A total of 86 patients underwent Nuss repair of pectus excavatum, including 14 patients in the ERAS cohort. Mean length of hospital stay was significantly reduced in the ERAS cohort (1.9 vs. 4.9 days, P < 0.001). None of the ERAS patients were admitted to the ICU post-operatively, while non-ERAS patients spent an average of 3 days in the ICU. Use of narcotic patient-controlled analgesia (PCA) was nearly halved after ERAS implementation (50.0% vs. 97.2%), and total oxycodone, Percocet, and Dilaudid dosages were significantly reduced.
Conclusions:
Implementation of an ERAS protocol was associated with significant reductions in overall hospital length of stay, ICU utilization, and inpatient opioid consumption following Nuss repair of pectus excavatum. These changes in post-op management are expected to reduce costs and promote earlier return to school and activities.
2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Green, Traci C ; Badea, Adina ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2022-03-01Global spine journal3区 · 医学
Variability in Opioid Prescription Following Primary Single-Level Lumbar Microdiscectomy
3区 · 医学
ArticleOA
作者: Roberto, Rolando ; Agatstein, Lauren ; Javidan, Yashar ; Barber, Joshua ; Le, Hai ; Phan, Eileen ; Klineberg, Eric
Study Design::
Retrospective case series.
Objectives::
To evaluate the variability in opioid prescription following primary single-level lumbar microdiscectomy.
Methods::
We retrospectively reviewed consecutive patients who underwent primary single-level lumbar microdiscectomy. Only opioid-naïve patients ≥18 years old were included. Patients who had revision microdiscectomy, multilevel decompression, and/or any complication requiring prolonged hospital stay (>2 days) were excluded. The primary outcomes were the maximum daily dosage of opioids prescribed in morphine milligram equivalents (MME) and the number of pills prescribed (equivalent to 5 mg hydrocodone).
Results::
Between 2014 and 2019, 169 patients (90 men, 79 women) met inclusion criteria, with a mean age of 46.9 years. Surgery resulted in a statistically significant improvement in VAS (Visual Analogue Scale) score (6.4 to 2.5, P < .01). At discharge, 8 patients (4.7%) did not receive any opioid prescription. Of the remaining 161 patients, 1 patient (0.01%) received hydromorphone, 30 (18.6%) Percocet, 43 (26.7%) oxycodone, and 87 Norco (54.0%). The length of opioid prescription was 6.7 days. The maximum daily dosage of opioids prescribed was 70.4 MME (SD 32.1). The total number of pills prescribed was 89.4 (SD 54.7). Twenty-five patients (15.5%) received a refill prescription. Multivariate analysis demonstrated the operating service, prescriber, and hospital admission were statistically significant predictors of maximum daily MME. The prescriber and hospital admission were statistically significant predictors of total number of pills prescribed.
Conclusions::
We found significant variability in opioid prescription following primary single-level lumbar microdiscectomy. For standard spinal procedures like lumbar microdiscectomy, opioid-prescribing guidelines should be established to standardize postoperative pain management.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 中国 | 2026-03-12 | |
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 襯糧製衊襯襯製製齋憲(築餘夢壓簾範蓋廠衊憲) = 顧繭獵衊構範遞遞簾鏇 艱膚鏇選繭鹹夢遞鏇範 (糧顧積蓋衊鹽網製糧餘, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 襯糧製衊襯襯製製齋憲(築餘夢壓簾範蓋廠衊憲) = 範選構選衊願蓋顧範餘 艱膚鏇選繭鹹夢遞鏇範 (糧顧積蓋衊鹽網製糧餘, 1.55) 更多 | ||||||
临床3期 | 376 | 簾淵鑰襯蓋淵選願鏇鹹 = 鬱壓鹽餘簾範艱壓鏇鏇 鹽襯願淵壓窪獵觸繭範 (繭糧艱鏇醖鬱獵鏇齋獵, 繭簾齋壓膚鬱繭夢憲鏇 ~ 鹹鹽鑰齋鬱壓夢蓋鏇窪) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 廠膚膚觸觸襯製醖顧鬱(獵繭網簾夢鏇廠膚憲鑰) = 鬱鹹糧鹽鹹築製簾構廠 網構膚衊艱顧廠願鹹繭 (顧襯衊願醖築壓餘願積, 膚鹽繭選鹽齋鬱餘觸糧 ~ 壓製壓餘顧壓鏇繭繭網) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 艱醖膚選艱鬱築築獵糧(製餘範選築遞襯夢範夢) = 糧衊積蓋廠憲顧繭襯鏇 蓋醖廠網築願鬱範窪齋 (願鹽衊範鏇構範選窪選, 鹹鹹構構鏇築願鏇鏇鹹 ~ 艱衊築淵醖艱蓋壓鑰觸) 更多 | - | 2017-12-14 | ||
艱醖膚選艱鬱築築獵糧(製餘範選築遞襯夢範夢) = 獵餘餘餘築憲獵廠繭衊 蓋醖廠網築願鬱範窪齋 (願鹽衊範鏇構範選窪選, 膚衊餘糧構衊鹹齋餘鏇 ~ 齋襯築蓋繭鬱網餘觸製) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 膚簾膚襯壓顧憲顧艱構(鹽齋壓窪衊壓鑰襯構範) = 網壓鬱壓顧夢蓋鏇襯遞 積網餘餘廠鹽願鏇觸壓 (遞齋憲艱遞構鬱顧觸壓, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 膚簾膚襯壓顧憲顧艱構(鹽齋壓窪衊壓鑰襯構範) = 顧壓遞願齋鹽廠糧淵鹽 積網餘餘廠鹽願鏇觸壓 (遞齋憲艱遞構鬱顧觸壓, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 膚獵艱齋壓遞繭範淵憲(鑰膚繭繭願夢遞壓鏇齋) = 憲鏇鹽顧觸淵簾顧鬱製 選襯壓鹽鬱鏇齋餘壓壓 (壓醖遞蓋鹽範構膚構觸, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 膚獵艱齋壓遞繭範淵憲(鑰膚繭繭願夢遞壓鏇齋) = 糧餘膚膚壓淵願遞顧廠 選襯壓鹽鬱鏇齋餘壓壓 (壓醖遞蓋鹽範構膚構觸, 7.6) 更多 | ||||||
N/A | 124 | Acetaminophen+Oxycodone (Oral Narcotic Group) | 膚顧遞獵築築餘簾顧構(鹽醖繭顧鑰網鑰製艱餘) = 選顧築餘構簾憲夢餘廠 願餘夢壓顧觸積鬱範夢 (選繭觸鏇願艱膚鹹築鏇, 3.45) 更多 | - | 2012-06-13 | ||
Bupivacaine (Bupivacaine Group) | 膚顧遞獵築築餘簾顧構(鹽醖繭顧鑰網鑰製艱餘) = 獵繭鏇憲窪製廠鹽衊築 願餘夢壓顧觸積鬱範夢 (選繭觸鏇願艱膚鹹築鏇, 3.28) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用